
How DP Clinical Leverages Medrio for Optimal Data Management
Learn how this CRO improved study timelines, participant experiences, and sponsor satisfaction.
Learn how this CRO improved study timelines, participant experiences, and sponsor satisfaction.
Discover how this CRO swiftly implemented Medrio CDMS/EDC, ensuring high-quality results and efficient processes for their client’s clinical trials.
Explore how Medrio empowers MAC’s early-phase trials with expert support, efficiency, and compliance.
Learn how Freenome found a robust partner in Medrio, helping them deliver data quality and compliance for large-scale oncology trials.
Discover how Medrio CDMS/EDC, eCOA/ePRO, and eConsent supported Swing Therapeutics in securing FDA clearance.
Medrio EDC has boosted HMR’s Statistics & Data Management group with an intuitive build functionality, automated query firing, and skip logic, increasing efficiency and accuracy. This scalable solution offers cost-effective data quality and exceptional service levels for sponsors, making the transition from paper-based processes seamless.
Emerging medical device company NeuraLace doubles clinical trial enrollment and demonstrates improved participant compliance with Medrio’s EDC and ePRO offerings.
Medrio’s electronic data capture (EDC) offers the speed, support, security, and ease of use necessary in the race to uncover biotech breakthroughs to improve the lives of people with diabetes.
RefleXion taps Medrio’s service and expertise to help build and launch the first studies for the breakthrough cancer treatment SCINTIX™ biology-guided radiotherapy.
Rose Research Center Counts on Medrio EDC and ePRO to simplify its transition from paper to digital data collection and increase the workflow efficiency of its tobacco cessation clinical studies.
Boutique CRO Atlantic Research Group (ARG) works with Medrio to simplify study builds for oncology, neurology and immunology trials. Medrio’s easy-to-use and flexible EDC solution unlocks new efficiencies and cost savings, ultimately helping ARG to stand out from the competition.
San Diego-based biotech trusts Medrio EDC for data collection. From drag-and-drop features to outstanding support, Medrio offers simplicity without compromise.
Collecting participant data securely is a critical part of running any clinical trial, whether it is decentralized, in-clinic, or somewhere in between. Medrio EDC and ePRO solutions are important assets that help CROs and sponsors do more with less.
The Digital Medicine Society (DiMe), an interdisciplinary professional society for digital medicine, was able to deploy Medrio’s eConsent module in less than two weeks to support its remote study to
Medrio helped Sciformix reduce the cost and timeline of the study. Medrio’s fully cloud-based platform made sharing easier which allowed Sciformix to work independently and efficiently.
inui Health creates innovative in-home consumer diagnostic tools for early detection of kidney disorders, UTIs, and general health issues. As a busy, quickly-growing startup with recent FDA approval to test
Advance Research Associates (ARA) has been helping pharmaceutical manufacturers and medical device companies succeed in clinical trials for more than 23 years. Having completed 700 studies for over 300 clients
It’s not often that two clinical data managers who are years apart in their experience feel equally at ease during a clinical trial. But this is precisely what took place
Clindata International, a South Africa-based CRO specializing in Animal Health clinical trials, has used Medrio EDC since 2013.
Swing Therapeutics leveraged Medrio ePRO in a proof-of-concept for a decentralized hybrid study. Electronic Patient-Reported Outcomes (ePRO) technology was used to assess the results of varying digital therapies and the
Paragonix Technologies selected Medrio EDC for their GUARDIAN-HEART clinical study. Electronic Data Capture (EDC) technology is being used to collect and manage registry data, examining the effect of controlled hypothermic
TargetCancer Foundation implemented Medrio’s remote consent function in their TCF-001 TRACK study, which has an objective to determine if rare tumors can benefit from matched molecular therapy. The study is
Sign up to have our the latest insights delivered to your inbox.